Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPYD | Q12882 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MAP3K7 | O43318 | 2/20 | 0.42 |
| ▸ | TAB1 | Q15750 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | TYR | P14679 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18640327 | 1.00 | DPYD (0.47) | DPYDALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL14405088 | 0.81 | DPYD (0.52) | DPYDALDH1A1MAPTKDM4EMAP3K7 | |
| SCHEMBL190328 | 0.81 | DPYD (0.59) | DPYDALDH1A1MAPTKDM4ECYP1A2 | |
| SCHEMBL190329 | 0.81 | DPYD (0.59) | DPYDALDH1A1MAPTKDM4ECYP1A2 | |
| SCHEMBL17991880 | 0.77 | HCAR2 (0.42) | DPYDALDH1A1MEN1KMT2ACYP1A2 | |
| SCHEMBL27253388 | 0.77 | DPYD (0.55) | DPYDALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL16784515 | 0.74 | MAP3K7 (0.45) | ALDH1A1MEN1KMT2AMAPTKDM4E | |
| SCHEMBL6374591 | 0.73 | DPYD (0.59) | DPYDALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL933037 | 0.73 | DPYD (0.59) | DPYDALDH1A1MAPTGAAATAD2 | |
| SCHEMBL6512588 | 0.73 | DPYD (0.59) | DPYDALDH1A1MAPTGAAATAD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 302 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026103877-A1 | LIPID COMPOUND AND LIPID NANOPARTICLE COMPOSITION | 中生复诺健生物科技(上海)有限公司 | 2026-05-21 | — | — | WO | disclosed |
| WO-2026106695-A1 | TARGETED NANOPARTICLES ENCAPSULATING WATER-SOLUBLE THERAPEUTICS, METHODS OF PRODUCTION, AND USE | OPTIMEOS LIFE SCIENCES, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| WO-2026098357-A1 | FREEZE-DRIED NUCLEIC ACID-LOADED LIPID NANOPARTICLE AND RECONSTITUTION METHOD THEREOF | KUDO BIOTECHNOLOGY, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20260130987-A1 | VACCINATION AGAINST PNEUMOCCOCAL AND COVID-19 INFECTIONS | PFIZER INC. (US) | 2026-05-14 | — | — | US | disclosed |
| WO-2026088119-A1 | LIPIDATED TLR7/8 MODULATORS AS ADJUVANTS AND USES THEREOF | PFIZER INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20260109977-A1 | MODIFIED RNA FOR INCREASING PROTEIN EXPRESSION | TRILINK BIOTECHNOLOGIES, LLC (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4728076-A1 | METHOD FOR STABILIZING RNA | Pfizer Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4720094-A1 | MUTATED FRAGMENT OF VZV GLYCOPROTEIN E | Suzhou Abogen Biosciences Co., Ltd. (CN) | 2026-04-08 | — | — | EP | disclosed |
| US-12594242-B2 | Lipid compounds and lipid nanoparticle compositions | Suzhou Abogen Biosciences Co., Ltd. (CN) | 2026-04-07 | — | — | US | disclosed |
| US-20260078082-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX INC (US) | 2026-03-19 | — | — | US | disclosed |
| WO-2017112865-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | MODERNATX, INC. (US) | 2017-06-29 | — | — | WO | disclosed |
| WO-2017066789-A1 | MRNA CAP ANALOGS WITH MODIFIED SUGAR | MODERNATX, INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| WO-2017066797-A1 | TRINUCLEOTIDE MRNA CAP ANALOGS | MODERNATX, INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| WO-2017066782-A1 | HYDROPHOBIC MRNA CAP ANALOGS | MODERNATX, INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| WO-2017066781-A1 | MRNA CAP ANALOGS WITH MODIFIED PHOSPHATE LINKAGE | MODERNATX, INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| WO-2017066791-A1 | SUGAR SUBSTITUTED MRNA CAP ANALOGS | MODERNATX, INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| WO-2017066793-A1 | MRNA CAP ANALOGS AND METHODS OF MRNA CAPPING | MODERNATX, INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| WO-2017049286-A1 | POLYNUCLEOTIDES CONTAINING A MORPHOLINO LINKER | MODERNA THERAPEUTICS, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| WO-2017049275-A2 | POLYNUCLEOTIDES CONTAINING A STABILIZING TAIL REGION | MODERNA THERAPEUTICS, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| WO-2017049245-A2 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109977-A1 | MODIFIED RNA FOR INCREASING PROTEIN EXPRESSION | RNGTT, RNMT, UPF1 | DPYD 1676/4885ALDH1A1 4457/4885MEN1 3384/4885 |
| US-20260130987-A1 | VACCINATION AGAINST PNEUMOCCOCAL AND COVID-19 INFECTIONS | SARS1, CD14, PYCARD | DPYD 4125/4885ALDH1A1 4675/4885MEN1 2650/4885 |
| US-12594242-B2 | Lipid compounds and lipid nanoparticle compositions | NPC1, NPC1L1, PLIN3 | DPYD 3574/4885ALDH1A1 4206/4885MEN1 3870/4885 |
| US-20260078082-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | PHOSPHO1, LIPC, SDCBP | DPYD 2943/4885ALDH1A1 4429/4885MEN1 2564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.